Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1488-1496

  Wu, Xiaomei ^a   Yan, Qin ^a   Zhang, Zhenbo ^a   Du, Guiqiang ^a   Wan, Xiaoping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adiponectin; AMPK; Eleptin; Endometrial neoplasms; STAT3

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ADIPONECTIN RECEPTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 6; JANUS KINASE; LEPTIN; LEPTIN RECEPTOR; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL CYCLE ARREST; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; METASTASIS INHIBITION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASES; LEPTIN; MEMBRANE PROTEINS; NEOPLASM METASTASIS; PROTEIN TRANSPORT; RECEPTORS, ADIPONECTIN; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84863286242     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/oror.2012.1670     Document Type: Article

References (45)

1. Cong L, Gasser J, Zhao J, Yang B, Li F and Zhao AZ: Human adiponectin inhibits cell growth induces apoptosis human endometrial carcinoma cells, HEC-1-A RL95 2. Endocr Relat Cancer 14: 713-720, 2007. (Pubitemid 350074060)
2. Ashizawa N, Yahata T, Quan J, Adachi S, Yoshihara K and Tanaka K: Serum leptin-adiponectin ratio and endometrial cancer risk in postmenopausal female subjects. Gynecol Oncol 119: 65-69, 2010.
3. Judd HL, Shamonki IM, Frumar AM and Lagasse LD: Origin of serumm estradiol in postmenopausal women. Obstet Gynecol 59: 680-686, 1982. (Pubitemid 12107424)
4. Berstein LM, Kvatchevskaya JO, Poroshina TE, et al: Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol 130: 687-693, 2004. (Pubitemid 39506383)
5. Kim KY, Baek A, Hwang JE, et al: Adiponectin-activated AMPK stimulates dephoshosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 69: 4018-4026, 2009.
6. Dalamaga M, Migdalis I, Fargnoli JL, et al: Pancreatic cancer expresses adiponectin receptors is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 20: 625-633, 2009.
7. Otake S, Takeda H, Fujishima S, et al: Decreased levels of plasma increased risk colorectal cancer. World J Gastroenterol 16: 1252-1257, 2010.
8. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, et al: Involvement of adiponectin and leptin breast cancer: clinical and vitro studies. Endocr Relat Cancer 16: 1197-1210, 2009.
9. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y and Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophy Res Commun 221: 286-289, 1996. (Pubitemid 26136463)
10. Nkhata KJ, Ray A, Schuster TF, Grossmann ME and Cleary MP: Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21: 1611-1619, 2009.
11. Takemura Y, Osuga Y, Yamauchi T, et al: Expression of adiponectin receptors its possible implication in the human endometriumm. Endocrinology 147: 3203-3210, 2006. (Pubitemid 43901111)
12. Nakayama S, Miyoshi Y, Ishihara H and Noguchi S: Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phasee entry without inducing apoptosis. Breast Cancer Res Treat 112: 405-410, 2008.
13. Landskroner-Eiger S, Qian B, Muise ES, et al: Proangiogenic contribution of adiponectin toward mammary tumor growthin vivo. Clin Cancer Res 15: 3265-3276, 2009.
14. De Vos P, Saladin R, Auwerx J and Staels B: Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 270: 15958-15961, 1995.
15. Mounzih K, Lu R Chehab FF: Leptin treatment rescues the sterility of genetically obese ob/males. Endocrinology 138: 1190-1193, 1997. (Pubitemid 27089777)
16. Lago F, Dieguez C, Gomez-Reino J and Gualillo O: The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18: 313-325, 2007. (Pubitemid 46891288)
17. Jarde T, Caldefie-Chezet F, Damez M, et al: Leptin and leptin receptor involvement cancer development: a study on human primary breast carcinoma. Oncol Rep 19: 905-911, 2008. (Pubitemid 351802658)
18. Guadagnini F, Roselli M, Martini F, et al: Prognostic significance of serum adipokine levels in colorectal patients. Anticancer Res 29: 3321-3327, 2009.
19. Chen DC, Chung YF, Yeh YT, et al: Serum adiponectin Taiwanese patients. Cancer Lett 237: 109-114, 2006.
20. Cleary MP, Ray A, Rogozina OP, Dogan S and Grossmann ME: Targeting the adiponectin:leptin ratio for postmenopausal cancer prevention. Front Biosci (Schol Ed) 1: 329-357, 2009.
21. Chen CL, Hsieh FC, Lieblein JC, et al: Stat3 activation human endometrial and cervical cancers. Br J Cancer 96: 591-599, 2007.
22. Yin N, Wang D, Zhang H, et al: Molecular mechanisms involved in growth stimulation breast cells leptin. Cancer Res 64: 5870-5875, 2004. (Pubitemid 39095588)
23. Jiang H, Yu J, Guo H, Song H Chen S: Upregulation of survivin leptin/STAT3 signaling in MCF-7 cells. Biochem Biophys Res Commun 368: 1-5, 2008.
24. Yamauchi T, Kamon J, Minokoshi Y, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002. (Pubitemid 35373562)
25. Jarde T, Perrier S, Vasson MP and Caldefie-Chezet F: Molecular mechanisms mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 47: 33-43, 2011.
26. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK and Sharma D: LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28: 2621-2633, 2009.
27. Soliman PT, Cui X, Zhang Q, Hankinson SE and Lu KH: Circulating adiponectin levels of cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol 204: 167 ee161-ee165, 2011.
28. Nyholm HC, Nielsen AL, Lyndrup J, Dreisler A, Hagen C and Haug E: Plasma oestro estrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 100: 1115-1119, 1993. (Pubitemid 24003622)
29. Pettersson B, Bergstrom R and Johansson ED: Serum estrogens and androgens in carcinoma. Gynecol Oncol 25: 223-233, 1986.
30. Benjamin F and Deutsch S: Plasma levels of fractionated pituitary hormones in endometrial carcinoma. Am J Obstet Gynecol 126: 638-647, 1976.
31. Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD and Ballon SC: Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 136: 859-871, 1980. (Pubitemid 10112650)
32. Calanog A, Sall S, Gordon GG and Southren AL: Androstenedione metabolism in patients with endometrial cancer. Am J Obstet Gynecol 129: 553-556, 1977. (Pubitemid 8226856)
33. Wu MH, Chou YC, Chou WY, et al: Circulating levels of leptin, adiposity and cancer risk. Br J Cancer 100: 578-582, 2009.
34. Li H, Stampfer MJ, Mucci L, et al: A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 56: 34-43, 2010.
35. Petridou E, Belechri M, Dessypris N, et al: Leptin body mass index in relation to endometrial cancer risk. Ann Nutr Metab 46: 147-151, 2002. (Pubitemid 34920698)
36. Tessitore L, Vizio B, Pesola D, et al: Adipocyte expression and circulating levels increase in both gynaecological and breast cancer patients. Int J Oncol 24: 1529-1535, 2004.
37. Yuan SS, Tsai KB, Chung YF, et al: Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. Gynecol Oncol 92: 769-775, 2004.
38. Tworoger SS, Eliassen AH, Kelesidis T, et al: Plasma adiponectin concentrations and risk incident cancer. J Clin Endocrinol Metab 92: 1510-1516, 2007. (Pubitemid 46556432)
39. Dos Santos E, Benaitreau D, Dieudonne MN, et al: Adiponectin mediates an antiproliferative responseonse in human MDA-MB 231 breast cancer cells. Oncol Rep 20: 971-977, 2008.
40. Kaaks R, Lukanova A and Kurzer MS: Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11: 1531-1543, 2002. (Pubitemid 36020003)
41. Saxena NK, Taliaferro-Smith L, Knight BB, et al: Bidirectional crosstalk between leptin insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation epidermal growth factor receptor. Cancer Res 68: 9712-9722, 2008.
42. Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidamidazole-4- carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593, 2005. (Pubitemid 41713917)
43. Sharma D, Saxena NK, Vertino PM and Anania FA: Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13: 629-640, 2006. (Pubitemid 43886682)
44. Buhler H and Schaller G: Transfection of keratin 18 gene in human breast cancer causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 3: 365-371, 2005. (Pubitemid 41045586)
45. Attoub S, Noe V, Pirola L, et al: Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 14: 2329-2338, 2000.